IQVIA Holdings Inc. $IQV Stake Boosted by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 97.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 133,384 shares of the medical research company’s stock after buying an additional 65,799 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in IQVIA were worth $21,020,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in IQV. Brighton Jones LLC grew its holdings in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares in the last quarter. Mutual of America Capital Management LLC grew its stake in IQVIA by 7.5% during the 1st quarter. Mutual of America Capital Management LLC now owns 34,435 shares of the medical research company’s stock valued at $6,071,000 after acquiring an additional 2,405 shares in the last quarter. Private Advisor Group LLC increased its holdings in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after purchasing an additional 566 shares during the period. Wedbush Securities Inc. purchased a new stake in shares of IQVIA in the first quarter worth approximately $256,000. Finally, AE Wealth Management LLC boosted its holdings in shares of IQVIA by 79.0% during the first quarter. AE Wealth Management LLC now owns 5,009 shares of the medical research company’s stock worth $883,000 after purchasing an additional 2,211 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Up 1.5%

IQV opened at $228.18 on Tuesday. The firm has a market cap of $38.86 billion, a P/E ratio of 31.30, a price-to-earnings-growth ratio of 2.52 and a beta of 1.34. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The business has a 50 day moving average price of $206.64 and a 200 day moving average price of $181.78. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $228.77.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Stifel Nicolaus increased their target price on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. Redburn Partners set a $214.00 target price on IQVIA in a research note on Wednesday, September 3rd. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and upped their target price for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $240.61.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.